Skip to content
Canadian orders above $200 ship free · Dispatched from Canadian stock

Buy Cagrilintide in Canada

Cagrilintide in Canada

Cagrilintide as lyophilised powder, offered in 5 mg and 10 mg vials. Every batch is HPLC tested and dispatched from Canadian stock. For laboratory research use only.

Format
Size
$43.00$8.60/mg
Dispatched from Canadian stock

Buy more, pay less per vial

Add 2 more to save 4%

Frequently bought together

At a glance
Also known as
Cagri · cagrilintide peptide · long-acting amylin analogue · CagriSema component
Class
Long-acting amylin analogue (amylin receptor agonist)
Form
Lyophilised powder, as 5 mg and 10 mg vials
Sizes
5 mg · 10 mg
Storage, dry
−20 °C, dry and dark
Storage, mixed
2–8 °C, use within 28 days of mixing (as generally reported for reconstituted peptides)
BAC water per size
5 mg: 2 mL · 10 mg: 2 mL

What is Cagrilintide?

Classified as a long-acting amylin analogue (amylin receptor agonist), Cagrilintide takes that label as the point from which its published record begins. The work published on it is in human. Several names in the literature all point to the same material, among them Cagri, cagrilintide peptide and long-acting amylin analogue. Its sequence is recorded as Amylin analogue modified for a long half-life; most trials pair it with semaglutide (CagriSema). All 8 of the 8 studies set out below are controlled trials in people. We keep it here as lyophilised powder in 5 mg and 10 mg vials, for laboratory work only. It is neither a medicine nor meant for use in humans or animals.

What the research shows

StudyModelDose usedDurationFinding
Lau DCW et al.2021 · Lancet · PMID 34798060Human, phase 2 randomised controlled trial, cagrilintide alone, adults with overweight or obesity without diabetes (n=906 randomised: 706 cagrilintide, 99 liraglutide, 101 placebo)Cagrilintide 0.3, 0.6, 1.2, 2.4 or 4.5 mg once weekly, subcutaneous; comparator liraglutide 3.0 mg once daily26 weeks treatment (including up to 6 weeks escalation), plus 6 weeks follow-upMean weight reduction was 6.0%–10.8% across the cagrilintide doses versus 3.0% with placebo (trial product estimand). Cagrilintide 4.5 mg reduced weight by 10.8% compared with 9.0% for liraglutide 3.0 mg.
Gabe MBN et al.2024 · Diabetes Obes Metab · PMID 39279639Human, randomised double-blind thorough QT study, cagrilintide alone, healthy participants (n=105)Cagrilintide once weekly subcutaneous, escalated to 4.5 mg; placebo arms received moxifloxacin 400 mg as a positive controlNot stated in the abstractNo clinically relevant QTcF prolongation occurred after the last 4.5 mg dose; the upper limits of the 90% confidence intervals of the placebo-adjusted changes were below 10 ms at all time points.
Enebo LB et al.2021 · Lancet · PMID 33894838Human, phase 1b randomised placebo-controlled trial, cagrilintide + semaglutide 2.4 mg, otherwise healthy adults with BMI 27.0–39.9 (n=96 randomised, 95 exposed)Cagrilintide 0.16, 0.30, 0.60, 1.2, 2.4 or 4.5 mg or placebo, each with semaglutide 2.4 mg, once weekly subcutaneousCo-escalation over 16 weeks, 4 weeks at target dose, then 5 weeks follow-upThe primary endpoint was the number of treatment-emergent adverse events; 566 adverse events were reported in 92 participants. Pharmacokinetics, body weight, glycaemic measures and hormones were secondary or exploratory endpoints.
Frias JP et al.2023 · Lancet · PMID 37364590Human, phase 2 randomised double-blind trial, CagriSema vs semaglutide vs cagrilintide, type 2 diabetes on metformin (n=92)CagriSema, semaglutide or cagrilintide, each escalated to 2.4 mg once weekly subcutaneous32 weeksHbA1c fell by 2.2 points with CagriSema, 1.8 with semaglutide and 0.9 with cagrilintide alone. Body weight fell by 15.6%, 5.1% and 8.1% respectively; CagriSema beat both single agents on weight.
Garvey WT et al.2025 · N Engl J Med · PMID 40544433Human, phase 3a randomised controlled trial (REDEFINE 1), CagriSema vs each component vs placebo, adults with overweight or obesity without diabetes (n=3417)Cagrilintide 2.4 mg + semaglutide 2.4 mg, semaglutide 2.4 mg, cagrilintide 2.4 mg, or placebo, once weekly68 weeksMean body weight change was −20.4% with CagriSema versus −3.0% with placebo (difference −17.3 percentage points). The abstract does not report the result for the cagrilintide-alone arm.
Davies MJ et al.2025 · N Engl J Med · PMID 40544432Human, phase 3a randomised placebo-controlled trial (REDEFINE 2), CagriSema, adults with overweight or obesity and type 2 diabetes (n=1206)Cagrilintide 2.4 mg + semaglutide 2.4 mg or placebo, once weekly68 weeksMean body weight change was −13.7% with CagriSema versus −3.4% with placebo. HbA1c of 6.5% or less was reached by 73.5% versus 15.9%.
Yamauchi T et al.2026 · Lancet Diabetes Endocrinol · PMID 42009015Human, phase 3a randomised active-controlled trial (REDEFINE 5), CagriSema vs semaglutide, adults in Japan and Taiwan with or without type 2 diabetes (n=331)Cagrilintide + semaglutide or semaglutide alone, both escalated to 2.4 mg once weekly subcutaneous68 weeksMean body weight change was −18.4% with CagriSema versus −11.9% with semaglutide alone (difference −6.5 percentage points).
Rosenstock J et al.2026 · Lancet · PMID 42251856Human, phase 3a randomised placebo-controlled trial (REIMAGINE 3), CagriSema added to basal insulin, type 2 diabetes (n=274)Cagrilintide 2.4 mg + semaglutide 2.4 mg, or 1.0 mg + 1.0 mg, or dose-matched placebo, once weekly subcutaneous40 weeksHbA1c fell by 2.33 points (2.4 mg each) and 2.10 points (1.0 mg each) versus 0.66 points with placebo.

What these studies don't show: Controlled human data does exist, yet its scope is narrow. The choice of who was enrolled, what was measured and over what period all bound the meaning of the results. Safety outside those trial conditions is still unestablished. Confirming that the vial contains what the label states tells you nothing about whether the compound has any effect.

Every study links to its PubMed record. See all Cagrilintide studies in the research library →

Cagrilintide price in Canada: 5mg and 10mg vials

Buy Cagrilintide in Canada in 2 vial sizes and a starter kit. Prices are in Canadian dollars, you pay by Interac e-Transfer or bank transfer, and orders are shipped from Canadian stock.

SizePricePer mg
5 mg$43.00$8.60/mg
10 mg$85.50$8.55/mg

Starter kit

Is Cagrilintide available in Canada?

Cagrilintide is not listed in the Drug Product Database as an authorized product. Health Canada has conducted no safety, efficacy or quality review of it. It stays here as laboratory research material and is not for use in a person or an animal. How Health Canada treats research peptides →

Side effects reported in studies

Every statement here is linked to the study that reported it. Any tolerability finding below is a direct quote from its source study. Human work on this scale does not pin down a safety profile.

Doses used in studies

Read more →

Cagrilintide FAQ

What is Cagrilintide?

Both suppliers and the literature record Cagrilintide as a long-acting amylin analogue (amylin receptor agonist). Its published work is in human. Borealis Peptides provides it as lyophilised powder in 5 mg and 10 mg vials for in-vitro laboratory research. It is neither a medicine nor meant for use in humans or animals. The studies behind it appear on this page, each with the model it used and what the authors reported.

Where can I buy Cagrilintide in Canada?

We ship it inside Canada from our own stock, in 5 mg and 10 mg vials. Nothing goes out until that batch has been confirmed by HPLC for identity and purity. Borealis Peptides takes research orders only and delivers to research and business addresses.

Is Cagrilintide legal in Canada?

Cagrilintide is not listed in the Drug Product Database as an authorized product. Health Canada has conducted no safety, efficacy or quality review of it. What we carry is laboratory research material alone, not for any use in a person or an animal. Because Health Canada has stated that "Research Use Only" labelling does not make a product legal to use in a person, we treat it as describing the intended supply and nothing more than that.

How much Cagrilintide should I use?

Borealis Peptides offers no dosing, protocols or reconstitution volumes and will not supply them even when asked. In the lab the quantity is dictated by the study design, something a supplier is in no position to set. The numbers on this page are simply what particular published studies used within their own models: a record of what was done, not a recommendation.

What human evidence is there for Cagrilintide?

Of the 8 studies cited, 8 are controlled trials in people, with the remainder being animal or cell work. Every row states its model, the amount used and the authors' reported finding, so each study's weight can be assessed first-hand instead of through a summary.

Does Cagrilintide need refrigeration?

While unopened, keep it at −20 °C in the dark. Once in solution, store at 2–8 °C. Since the dry form holds up at room temperature, shipping calls for no cold chain; put it in the fridge on arrival. The real risks are repeated freeze-thaw cycles and light exposure, not the shipping itself.

How is the purity of Cagrilintide confirmed?

Identity and purity are verified by HPLC for every batch rather than once per product. The certificate states which batch it covers, and that batch number is printed on the vial, so any result can be traced back to the exact material behind it. Send us your order number and we forward it.

How does Cagrilintide compare with Retatrutide and Tirzepatide?

They are distinct compounds with distinct published records, and this site does not rank them. Retatrutide and Tirzepatide have 6 cited studies and 8 cited studies on their page against 8 here. The comparison that helps is between the two study tables and the models behind them.

Compare with